Pharmacovigilance in Nigeria is the monitoring, assessment and prevention of adverse effects and other medicine related problems for products on the Nigerian market. It is regulated by the National Agency for Food and Drug Administration and Control (NAFDAC). Any company holding a NAFDAC Certificate of Registration for a medicinal product must operate a pharmacovigilance system, have a Qualified Person for Pharmacovigilance (QPPV) who resides in Nigeria, maintain a Pharmacovigilance System Master File held in Nigeria, report suspected adverse reactions to NAFDAC, detect and manage safety signals, manage product risks and keep records that prove all of it. This guide explains each requirement and links to MedNova's detailed article on it.
What pharmacovigilance means in Nigeria
NAFDAC adopts the World Health Organization definition of pharmacovigilance: the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine related problem. Its purpose is to keep medicines safe after they reach patients, because clinical trials are too small, too short and too selective to reveal every risk. MedNova's glossary entries on Good Pharmacovigilance Practice and the adverse drug reaction give the short definitions.
This matters more in Nigeria than a global safety profile suggests. Most medicines sold in Nigeria were developed and studied in other populations. Nigerian patients differ in genetics, disease burden, nutrition, concurrent use of herbal and traditional preparations, storage conditions and patterns of self medication. A product's safety in Nigeria has to be observed in Nigeria.
Who regulates pharmacovigilance in Nigeria
NAFDAC regulates pharmacovigilance under the NAFDAC Act, Cap N1, Laws of the Federation of Nigeria 2004. Three parts of the national system matter to companies:
PV and Post Marketing Surveillance Directorate
The NAFDAC directorate responsible for drug safety policy, guidelines and oversight.
National Pharmacovigilance Centre
Based at NAFDAC headquarters, it receives and manages safety reports and coordinates national pharmacovigilance activity.
Zonal pharmacovigilance centres
Hosted at teaching hospitals and federal medical centres across the geopolitical zones, they collect reports closer to where patients are treated.
Nigeria joined the WHO Programme for International Drug Monitoring in 2004. National reports are managed in VigiFlow and shared with VigiBase, the WHO global database operated by the Uppsala Monitoring Centre. A Nigerian case therefore becomes part of global safety surveillance.
The regulator's standing has risen sharply. NAFDAC attained WHO Maturity Level 3 in 2022 and has sustained it through re-benchmarking, and in November 2025 it became a full Regulatory Member of the International Council for Harmonisation. Our comparison of ICH guidelines and NAFDAC requirements explains what that membership means for pharmacovigilance.
The legal framework: regulations and guidelines
Two documents form the core of Nigerian pharmacovigilance law and practice.
Good Pharmacovigilance Practice Regulations, 2021
Set the legal duties every Certificate of Registration Holder must meet.
NAFDAC Good Pharmacovigilance Practice Guidelines
Chapters on the PV system, the master file, risk management, safety communication, ADR reporting, PSURs, post authorisation safety studies and audit.
NAFDAC also publishes guidelines for post marketing surveillance of medical products, and the pharmacovigilance and post market surveillance guidelines index lists current editions.
The GVP guidelines do not cover safety reporting in clinical trials. That falls under NAFDAC's Good Clinical Practice Regulations, so a company running trials and marketing products operates two parallel pathways. Our guide to NAFDAC pharmacovigilance requirements walks through the guidelines chapter by chapter.
Who must comply
The obligations fall on the Certificate of Registration Holder, a term NAFDAC defines broadly. It includes NAFDAC licence holders, individuals, public and private institutions, manufacturers, importers and donors of medicinal products. Applicants for and holders of listings for traditional herbal medicinal products must also submit a master file.
The guidelines also name products expected to be under active safety monitoring, including:
- Products developed wholly or largely outside Nigeria
- Products with under ten years of post marketing experience elsewhere, or under five years in Nigeria
- Products subject to a risk management plan in any other country
- Products granted accelerated or conditional approval anywhere
- Biologicals, products acting on the immune system, and central nervous system products
- Orphan products and products for special populations such as children and the elderly
Falling outside these categories does not remove the general duty to monitor every product a company markets.
The eight building blocks of a compliant pharmacovigilance system
NAFDAC defines a pharmacovigilance system as a quality system covering organisational structure, responsibilities, procedures, processes and resources, with resource management, compliance management and record management. In practice, that means eight building blocks.
A Qualified Person for Pharmacovigilance
The holder must have an appropriately qualified QPPV permanently and continuously at its disposal, and the QPPV should reside and operate in Nigeria. The QPPV needs authority over the system and the master file, a documented deputy, access to safety data at any time, and acts as NAFDAC's single pharmacovigilance contact point on a 24 hour basis. See our guide to the QPPV in Nigeria and our QPPV Support Essentials.
Competent, trained people
Beyond the QPPV, the holder needs enough competent, trained staff for its portfolio. Training must also reach staff outside pharmacovigilance whose work can affect it, including sales and marketing, product complaints, medical information, regulatory affairs, clinical trials, legal and audit.
Written procedures
Every element of the quality system must be documented in written policies and procedures: case intake and validation, follow up, submission, signal management, safety communication, deviations and corrective action, archiving and business continuity.
The Pharmacovigilance System Master File
The master file describes the system. It must be maintained, available to NAFDAC on request, located at the Nigerian site of the main pharmacovigilance activities or where the QPPV operates, and submitted during application for a Certificate of Registration. It must carry a change logbook, performance figures and a five-year audit list.
Case management and reporting
The holder must collect suspected adverse reactions from all solicited and unsolicited sources, validate them against the four minimum criteria (an identifiable patient, an identifiable reporter, a suspect product and a suspected reaction), follow up, assess seriousness and expectedness, and report to NAFDAC within the applicable timeframe. The master file must show measured timeliness of 15-day and 90-day reporting over the past year. Our walkthrough of what happens after you report an adverse event to NAFDAC follows a case through the national system.
Signal detection
Signal detection and management is a named critical process. Cases must be reviewed in aggregate, not only one by one, using a documented method, with the outcome and actions recorded. Our article on signal detection in pharmacovigilance in Nigeria explains why standard statistical methods underperform on small Nigerian datasets and what to do instead.
Risk management and periodic reporting
Where required, the holder maintains a risk management plan in seven parts, with a safety specification that includes the epidemiology of the indication in Nigeria, and monitors whether risk minimisation measures work. Periodic safety update reports are scheduled and submitted as the Agency specifies. See the glossary entry on the Risk Management Plan.
Audit, records and corrective action
The holder must audit its pharmacovigilance system, including delegated activities, track corrective and preventive actions to verified closure, and keep records that are complete, retrievable, traceable and access controlled. NAFDAC may inspect at any time.
Our breakdown of what GVP compliance means in Nigeria covers these building blocks in detail, with a full compliance checklist.
How adverse event reporting works in Nigeria
Healthcare professionals and patients can report suspected adverse reactions using NAFDAC's ADR forms, also called yellow forms, available at NAFDAC state offices, the National Pharmacovigilance Centre and the zonal centres, or through NAFDAC's online ADR reporting channels and the Med Safety mobile app. For Certificate of Registration Holders, reporting is a legal obligation, not a choice.
Digital reporting changed the volume of safety data dramatically. A published analysis of reporting before and after the Med Safety App recorded:
More patients now report straight to NAFDAC, which means the regulator increasingly sees cases a company may have missed.
Nigeria within African safety surveillance
Nigerian pharmacovigilance no longer stops at the border. Nigeria was a founding country of the African Union Smart Safety Surveillance programme, which supported cross border vaccine safety surveillance during the COVID-19 rollout. In January 2026 that programme transferred to the African Medicines Agency.
For companies, reporting obligations remain with NAFDAC, but safety signals for the same product in other African markets are increasingly visible to Nigerian regulators. Our article on what the African Medicines Agency means for NAFDAC registered companies covers the implications, and our comparison of WHO prequalification and NAFDAC registration covers the procurement side.
Where companies most often fall short
A 2018 situational analysis of pharmacovigilance in Nigeria, prepared with NAFDAC, recorded concern about the competence of some QPPVs appointed by marketing authorisation holders and found that safety update reports often lacked Nigeria specific data. The same weaknesses still appear today:
- Reporting without a systemCases get submitted, but no procedures, monitoring or quality system sit behind them.
- A QPPV in name onlyNo authority, no deputy, no out of hours access, or not based in Nigeria.
- Cases lost at the edgesSafety information reaches sales, quality or distributors and never reaches pharmacovigilance.
- No signal detectionCases are processed individually and never reviewed together.
- No evidenceThe work happens but is not recorded, measured or audited, and the master file goes stale.
Our diagnostic guide to the five pharmacovigilance compliance mistakes Nigerian pharma companies make covers each of these in depth, with the fix and the evidence to retain.
How to resource pharmacovigilance: in-house or outsourced
Companies resource the function in one of three ways.
Fully in-house
Suits companies with a large Nigerian portfolio and the volume to justify a dedicated team, safety database and resident QPPV.
Hybrid
A global safety department handles case processing and aggregate reports, while a local partner provides the resident QPPV, local intake, literature monitoring and NAFDAC liaison. The most common model for multinationals.
Fully outsourced
A service provider runs the system end to end. Common for smaller companies, importers and new market entrants.
NAFDAC permits outsourcing, including the QPPV role, but responsibility never transfers. Delegated work needs a written contract, a description in the master file and a listed subcontract, and the vendor may itself be inspected. The holder remains accountable for the quality and integrity of the whole system.
A starting checklist
Pharmacovigilance in Nigeria: minimum position
- QPPV resident in Nigeria, notified to NAFDAC, with a documented deputy
- Written procedures covering every critical pharmacovigilance process
- Pharmacovigilance System Master File held in Nigeria, with a current logbook
- All intake channels mapped, and non pharmacovigilance staff trained
- Reporting timeliness measured, not assumed
- Documented signal detection on a fixed cycle
- Risk management plans and periodic reports scheduled where required
- Pharmacovigilance agreements with every partner, distributor and vendor
- Audit schedule in place, with corrective actions tracked to closure
For a structured self assessment, download the NAFDAC QPPV Compliance Checklist or take the free MedNova PV readiness assessment, which returns an instant readiness score. Our PV Readiness Guide covers inspection preparation.
Take the PV Readiness AssessmentFrequently asked questions
What is pharmacovigilance in Nigeria?
It is the detection, assessment, understanding and prevention of adverse effects and other medicine related problems for products on the Nigerian market, regulated by NAFDAC under the NAFDAC Act and its Good Pharmacovigilance Practice Regulations and Guidelines.
Who regulates pharmacovigilance in Nigeria?
NAFDAC, through its Pharmacovigilance and Post Marketing Surveillance Directorate and the National Pharmacovigilance Centre in Abuja, supported by zonal pharmacovigilance centres.
Who must comply with NAFDAC pharmacovigilance requirements?
Every Certificate of Registration Holder, including licence holders, manufacturers, importers, institutions and donors of medicinal products. Holders of traditional herbal medicine listings must also submit a master file.
Does a company need a QPPV in Nigeria?
Yes. The holder must have an appropriately qualified QPPV permanently and continuously at its disposal, and the QPPV should reside and operate in Nigeria.
What is a Pharmacovigilance System Master File?
A document describing the company's pharmacovigilance system. In Nigeria it must be held at the site of the main pharmacovigilance activities or where the QPPV operates, and submitted with the registration application.
How are adverse events reported in Nigeria?
Healthcare professionals and patients can use NAFDAC's ADR forms, online reporting and the Med Safety app. Certificate of Registration Holders are legally required to report suspected adverse reactions to NAFDAC within the applicable timeframes.
Is signal detection required in Nigeria?
Yes. Signal detection and management is a named critical process in NAFDAC's guidelines, and the method and outcomes must be documented.
Can pharmacovigilance be outsourced in Nigeria?
Yes, including the QPPV role, under a written contract. The Certificate of Registration Holder keeps full responsibility for the system.
Do NAFDAC's GVP guidelines cover clinical trials?
No. Clinical trial safety reporting falls under NAFDAC's Good Clinical Practice Regulations.
Does Nigeria share safety data internationally?
Yes. Nigeria has been part of the WHO Programme for International Drug Monitoring since 2004, and national reports are shared with the WHO global database, VigiBase.
How MedNova supports pharmacovigilance in Nigeria
MedNova Lifesciences provides pharmacovigilance services in Nigeria: local QPPV representation, pharmacovigilance system setup and SOPs, case processing, aggregate reporting, signal detection and risk management, weekly literature surveillance, inspection readiness and corrective action support. We also provide regulatory affairs support including NAFDAC product registration, clinical development services and training and consulting. See our capability statement or browse the resources library.
Next step
Take the MedNova PV readiness assessment for an instant readiness score, or contact our team to discuss your pharmacovigilance system.
Take the PV Readiness Assessment Contact MedNova LifesciencesRelated resources
References
- National Agency for Food and Drug Administration and Control. NAFDAC Good Pharmacovigilance Practice Guidelines (Doc. Ref. PV/PMS-GDL-017-01).
- National Agency for Food and Drug Administration and Control. Good Pharmacovigilance Practice Regulations, 2021.
- National Agency for Food and Drug Administration and Control. Guidelines for Post Marketing Surveillance of Medical Products in Nigeria.
- National Agency for Food and Drug Administration and Control. Pharmacovigilance and Post Market Surveillance Guidelines index.
- National Agency for Food and Drug Administration and Control. Handling Adverse Drug Reactions (ADRs).
- Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria. Pharmaceutical Medicine, 2024. PubMed record 38705932.
- Uppsala Monitoring Centre. Operating the WHO Programme for International Drug Monitoring.
- World Health Organization. Egypt and Nigeria medicines regulators achieve high maturity level in WHO classification, 30 March 2022.
- National Agency for Food and Drug Administration and Control. NAFDAC's WHO ML3 re-benchmarking success.
- National Agency for Food and Drug Administration and Control. NAFDAC announces a transition from observer status to full membership of the ICH.
- AUDA-NEPAD. African Union Smart Safety Surveillance (AU-3S).
- African Medicines Agency. AMA and AUDA-NEPAD conclude the transition of continental medicines regulatory programmes, 23 January 2026.
- KNCV Tuberculosis Foundation, NAFDAC and partners. Pharmacovigilance in Nigeria: a situational analysis at the start of the PAVIA project, 2018.
- MedNova Lifesciences. Pharmacovigilance services, Nigeria and Africa. mednovalife.com/pv.html
- MedNova Lifesciences. Regulatory affairs services, Nigeria and Africa. mednovalife.com/regulatory.html